Skip to main content
European Commission logo print header

Profiling metalloprotease inhibition for tumour therapy

Ziel

Inhibitors of metalloproteinases have shown a high therapeutic potency in preliminary clinical trials. However, unacceptable side-effects are associated, which are relative to recently discovered ADAMS and "non classical" effects of MMPs. This project aims at defining the best MMP inhibition profiles for cancer therapy by
1) a comprehensive assessment of metalloprateinase activities and functions at both physiological and tumour progression level, i.e. by using first inhibition inhibitors as probe;
2) designing new metalloproteinase inhibitors on the basis of inhibitor-enzyme complex 3-D structures and on the biological activities to be tackled;
3) assessing the benefit of combining MMP inhibitors with serine proteases inhibitors designed on a similar basis.

Aufforderung zur Vorschlagseinreichung

Data not available

Koordinator

UNIVERSITE DE LIEGE*ULG
EU-Beitrag
Keine Daten
Adresse
PLACE DU 20 AOUT 7
4000 LIEGE
Belgien

Auf der Karte ansehen

Gesamtkosten
Keine Daten

Beteiligte (9)